复宏汉霖盘中涨超10% 汉贝泰成为公司第四款在海外获批上市产品

新浪港股
06 Mar
热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易
客户端

  复宏汉霖(02696)盘中一度涨超10%,2月初至今股价累计涨幅已接近90%。截至发稿,股价上涨6.43%,现报29.80港元,成交额3949.73万港元。

  复宏汉霖近期公告称,公司自主开发和生产的汉贝泰(贝伐珠单抗注射液)正式获得玻利维亚国家药品与卫生技术局批准上市,标志着汉贝泰成为继汉曲优(曲妥珠单抗)、H药汉斯状(斯鲁利单抗)、汉利康(利妥昔单抗)后,复宏汉霖第四款在海外获批上市的自主研发和生产的产品。

海量资讯、精准解读,尽在新浪财经APP

责任编辑:卢昱君

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10